2020

第五届中国医药创新与投资大会

2020 China BioMed Innovation and Investment Conference

CBIIC

2020 CBIIC will further open financing channel for pharmaceutical innovation, focus on China's latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle.

第五届中国医药创新与投资大会将继续贯彻打通医药创新投融资渠道，围绕医药创新热点问题，深度聚焦科技创新成果和全球投融资新动态、新趋势，分享我国最新医药产业政策。

路演项目审核专家名单

Expert Review Committee List

蒋华良
JIANG Hualiang

中国科学院院士、
中国药促会 2015–2016 年度会长、
中国科学院上海药物研究所研究员
Academician of Chinese Academy of Sciences
2015-2016 Annual Chairman of PhIRDA
Professor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences

蒋建东
JIANG Jiandong

中国药促会 2017–2018 年度会长、
中国医学科学院药物研究所所长
2017-2018 Annual Chairman of PhIRDA
Director of Institute of Materia Medica, Chinese Academy of Medical Sciences

石远凯
SHI Yuankai

中国药促会药物临床研究专业委员会副主任委员、中国医学科学院肿瘤医院副院长
Vice-Chairman of PhIRDA Clinical Research Specialty Committee
Vice President of Cancer Hospital, Chinese Academy of Medical Sciences

李　佳
LI Jia

中国科学院上海药物研究所所长、
新药研究国家重点实验室主任
Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Director of State Key Laboratory of Drug Research

陈晓光
CHEN Xiaoguang

中国医学科学院药物研究所教授
Professor of Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College

王印祥
WANG Yinxiang

中国药促会药物研发专委会主任委员、
北京加科思新药研发有限公司董事长
Chairman of PhIRDA Drug R&D Specialty Committee
Chairman of the Board, Jacobio Pharma

谭凌实
TAN Lingshi

中国药促会创新研发服务专业委员会主任委员、缔脉生物医药科技（上海）有限公司董事长兼首席执行官
Chairman of PhIRDA Innovation R&D Services Specialty Committee
Chairman of the Board & CEO, dMed Biopharmaceutical

房健民
FANG Jianmin

中国药促会药物研发专委会副主任委员、荣昌生物制药（烟台）有限公司 CEO、首席科学官
Vice-Chairman of PhIRDA Drug R&D Specialty Committee
CEO & CSO of RemeGen

杨大俊
YANG Dajun

中国药促会药物研发专委会副主任委员、亚盛医药董事长兼 CEO
Vice-Chairman of PhIRDA Drug R&D Specialty Committee
Chairman of the Board & CEO, Ascentage Pharma

CBIC

大会简介

Introduction of CBIIC

中国医药创新与投资大会（以下简称“创投大会”）是由中国医药创新促进会（以下简称“中国药促会”）于 2016 年发起创办的医药界与投资界高端对话平台。创投大会始终坚持以“推动社会资本与医药创新相结合，提高医药创新能力”为宗旨，聚焦产业政策、全球医药研发趋势和投融资动向，为业界领袖、专家、学者以及国内外医药创新企业和投资人，搭建权威、专业、多维度的对话沟通平台，深入探讨创新发展新趋势、共商投资合作新战略。

2016–2019 年中国药促会先后携手中国证券业协会、中国医疗器械行业协会、香港交易所、中国医院协会、蓝迪国际智库等机构成功举办了四届创投大会，累计参会人数超过 10,000 人，2,100 余家国内外医药相关企业和 1,500 余家投资机构到会路演，33 个创新品种在大会进行了临床数据全球首发，450 多个国内外创新项目通过路演展示，被誉为“亚太地区最受关注的医药创新与投资合作平台”。

为推动新冠疫情下全球资本与我国医药创新的深入合作，促进医药创新活力充分释放与创新成果及时、高效转化，共建后疫情时代医药产业新格局，第五届创投大会定于 2020 年 9 月 27 日 –29 日在苏州工业园区举办。

一 、贯彻推动医药创新理念，优化专场设置以满足不同参会者需求

2020 年，中央政治局常务委员会会议首次将生物医药纳入我国支柱产业范畴，全面提升生物医药产业创新发展能力。第五届创投大会将继续贯彻打通医药创新投融资渠道，围绕医药创新热点问题，深度聚焦科技创新成果和全球投融资新动态、新趋势，分享我国最新医药产业政策，设置多个热门领域路演专场，包括临床数据首发、上市及非上市、医疗器械、国际肿瘤药及国际项目、大数据 + 智慧医疗、AI+ 生物医药、创新研发服务（CRO、CMO、CDMO）等路演专场，以及投资人经验分享、融资并购和医药政策论坛等近二十场精彩纷呈、特色鲜明的交流活动，创新项目将涉及创新药、孤儿药、免疫疗法、AI 药物设计、互联网医疗、大数据 – 智慧医疗、基因检测和创新型医疗器械等前沿创新项目，满足不同参会者的需求。

二 、国家权威机构全力支持，全球顶尖机构深入合作

本届创投大会将继续与相关政府部门、国内外知名机构深入合作，邀请行业领袖、顶级专家学者热议全球医药创新及投融资政策和发展趋势，助力我国医药产业创新转化能力提升。

历届大会均得到了国内外权威机构的大力支持，包括：中国医学科学院、中国中医科学院等学术权威机构；加拿大、荷兰、澳大利亚等驻华使领馆；美国癌症研究基金会、日本制药工业协会等国际组织；香港中资证券业协会、加拿大多伦多证券交易所等国际金融机构。此外，摩根大通（J.P.Morgan）连续多届作为独家国际金融机构赞助商为大会提供全方位鼎力支持。

三 、商务洽谈邀约，深度对话为参会者提供零距离交流平台

为促进国内外医药创新与投资界的有效交流与精准合作，创投大会持续搭建更加丰富多样的展示与交流平台。本届大会将持续为参会企业提供商务洽谈邀约服务。投资人和路演汇报人可通过邀约系统寻找潜在客户、合作伙伴，在线向对方发起邀请，与会期间可与对方实现面对面交流洽谈，实现零距离无障碍沟通，深度对话碰撞出更多商机。

四、国内外媒体积极关注，见证创新与投资的融合

自 2016 年以来，创投大会得到包括《Nature》、人民网、健康报、中国医药报、医药经济报在内的数十家国内外著名杂志和权威传统媒体支持；同时吸引了包括 PharmaBoardroom、界面、36 氪、财新传媒等新媒体和医药财经类行业媒体参会，并对大会实时报道，共同见证创新与投资的融合。

在各方的共同协作与鼎力支持下，创投大会正在逐步成为解读中国医药和投融资政策、展示国内外医药创新成果和引领投资新动向的具有广泛国际影响力、权威性、多元化的成果转化及权威合作交流平台，逐渐成为亚太地区最具影响力的年度品牌盛会。创投大会将继续在社会资本与医药创新发展历程中发挥引领作用，创造更加科学、更富吸引力的医药创新投资环境，为我国经济社会发展、满足临床用药需求、打造健康中国贡献力量。



大会简介

Introduction of CBIIC

China BioMed Innovation and Investment Conference (CBIIC), as an annual grand conference to promote the communication between pharmaceutical industry and investment industry, was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. To promote the linkage between social capital and pharmaceutical innovation and improve the innovation capability of pharmaceutical industry, CBIIC focuses on China's latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle. CBIIC was built as an authorized, comprehensive, professional and international high level platform for the industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises and investors to learn the trend of innovation and discuss new investment channels and innovative cooperation strategies.

Established by PhIRDA, CBIIC was successively co-hosted by Securities Association of China (SAC), China Association for Medical Devices Industry (CAMDI), Hong Kong Exchanges and Clearing Limited (HKEX) and Chinese Hospital Association (CHA), Research and Development International (RDI) from 2016 to 2019. By the end of 2019, CBIIC has attracted over 10,000 participants, 2,100 domestic and foreign pharmaceutical enterprises and 1,500 investment institutions, and 33 new drugs made global first clinical trial data release, 450 innovative projects at home and abroad made roadshows in this events, including 80 international projects. CBIIC received extensive attention and was praised as the "most popular cooperation platform for pharmaceutical innovation and investment in Asian-Pacific region".

To promote the in-depth cooperation between global capital and pharmaceutical innovation in China under the background of COVID-19, facilitate the release of vitality of pharmaceutical innovation and timely transformation of unmet clinical needs, jointly building the new pattern of post-pandemic era for pharmaceutical industry, PhIRDA will host 2020 CBIIC in Suzhou Industrial Park on September 27-29, 2020.

I.Implement the Pharmaceutical Innovative Concept and Improve Setting of Parallel Sessions

To improve China's biopharmaceutical innovation ability in all levels, biopharmaceutical industry has been included into the national central pillar industries for the first time on the Standing Committee of the Political Bureau of the Central Committee of the CPC in 2020. 2020 CBIIC will further open financing channel for pharmaceutical innovation, focus on China's latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle. 2020 CBIIC will include almost 20 fascinating and excellent parallel sessions such as Clinical Trial Data Release, Roadshows for Listed and Non-Listed Companies, Medical Devices, International Oncology Drugs, International Projects, WIT MED + Big Data, Artificial Intelligence (AI) + BioMed, Service Companies (CRO/CMO/CDMO) and Service Agencies and forums for Investors' Experience Sharing, Financing M&A and Latest Drug Policy Sharing. The roadshow projects will cover the cutting-edge areas including biopharmaceutical, oncology drugs, orphan drugs, immunotherapy, AI for drug design, biotechnology, Virtual Healthcare, medical big data, gene detection, innovative medical devices, meeting diversified needs of participants.

II.Great Supports from National Authorized Institutions & In-depth Cooperation with Global Top Leading Organizations

2020 CBIIC will make further cooperation with government departments and well-known institutions around the world, and invite KOLs in pharmaceutical industry and leading experts to discuss policies and trends of global pharmaceutical innovation and financing to improve China's capability on transformation and innovation in pharmaceutical industry.

Since its establishment, CBIIC has received great support from prestigious institutions in China and around the world, including Chinese Academy of Medical Sciences, China Academy of Chinese Medical Sciences and authorized academic institutions; Canada, the Netherlands, Australia and other embassies and consulates in China; National Foundation for Cancer Research (NFCR), Japan Pharmaceutical Manufacturers Association (JPMA) and international organizations; Chinese Securities Association of Hong Kong (CSAHK), TMX Group Limited and global financing institutions. Moreover, J.P. Morgan supports CBIIC as the exclusive international financial institution sponsor for several times.



III.One-on-One Partnering System Provides Close Communication for Participants

To facilitate effective communication and precise cooperation between domestic and foreign pharmaceutical innovators and investors, 2020 CBIIC will build a better and more diverse platform for project presentation and communication. One-on-One partnering service will be provided for participants. Investors and roadshow speakers could propose an invitation in this system online easily and efficiently. In this event, participants will have face-to-face communication and negotiation to seek potential opportunities for further collaboration.

IV.Great Attention from Domestic and Global Medias and Witness the Integration of Innovation and Investment

Since 2016, CBIIC was supported by over ten well-known magazines and traditional medias at home and abroad, including *Nature*, *people.cn*, *JKB.com.cn*, *China Pharmaceutical News*, *Medicine Economic Reporter*, and attracted new medias and healthcare financial medias including PharmaBoardroom, Jiemian.com, 36 Kr, Caixin Media, to make real-time report of the event and witness the integration of innovation and investment.

Under the great support of all parties, CBIIC is gradually becoming an international, authoritative, diversified communication platform to interpret policies on drug and financing and investment circle, present pharmaceutical innovative achievements at home and abroad, lead new investment trends. As the most influential annual grand conference in Asia-Pacific region, CBIIC will make social capital playing a leading role in the development of pharmaceutical innovation, create a more scientific and attractive investment environment and contribute to China's economic and social development to meet the clinical needs and advance the pursuit of Healthy China.

会议组织机构

Conference Organization

主办单位

中国医药创新促进会

中国医疗器械行业协会

香港交易所

艾美达（北京）医药信息咨询有限公司

独家国际金融机构赞助商

摩根大通

协办单位

华平投资

先声药业

西安杨森制药有限公司

高特佳投资

Hosts

China Pharmaceutical Innovation and Research Development Association (PhIRDA)

China Association for Medical Devices Industry (CAMDI)

Hong Kong Exchanges and Clearing Limited (HKEX)

iMeta Health Information Consulting Co., Ltd.

Exclusive International Financial Institution Sponsor

J.P. Morgan

Co-Organizers

Warburg Pincus

Simcere Pharmaceutical Co., Ltd.

Xian Janssen Pharmaceutical Ltd.

GTJA Investment Group

支持单位

中国医学科学院
南方医药经济研究所
苏州工业园区
中关村股权投资协会
香港生物医药创新协会
台湾生技医疗产业策进会
日本制药工业协会
BioCentury
中国外商投资企业协会药品研制和开发行业委员会
加拿大驻沪总领事馆

媒体支持

施普林格·自然集团
医药经济报
米内网
医学前沿

Supporters

Chinese Academy of Medical Sciences
Southern Medicine Economic Research Institute
Suzhou Industrial Park
Zhongguancun Private Equity & Venture Capital Association (ZVCA)
HK Bio-Med Innotech Association (HKBMIA)
Institute for Biotechnology and Medicine Industry (IBMI)
Japan Pharmaceutical Manufacturers Association (JPMA)
BioCentury
China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC)
Consulate General of Canada in Shanghai

Supporting Media

Springer Nature
Medicine Economic Reporter
MENET
NEJM Frontiers in Medicine

主持人：梁燕，荷兰王国驻华大使馆生命科学和医学官员
Moderator: Sunny LIANG, LSH Officer, Department of Health, Welfare and Sport, Embassy of the Kingdom of the Netherlands

15:00-15:05

Peter A. Bootsma
荷兰王国驻华大使馆卫生、福利和体育参赞
Counselor of Health, Welfare and Sports, Embassy of the Kingdom of the Netherlands
开场致辞 Welcome Remarks

15:05-15:25

Troels Jordansen
CEO, Glycostem
项目 1: 癌症杀手：自然杀伤细胞抗癌药
Project 1: NK Cells: The Killer of Cancer

15:25-15:45

Axel Mescheder
CEO, Cristal Therapeutics
项目 2: 改善癌症和其他疾病治疗效果的纳米药物
Project 2: Customized Nanomedicines with Superior Therapeutic Profiles

15:45-16:05

Jeroen Tonnaer
BD & Licensing, PureIMS
项目 3: 可快速投放市场的低成本预装式一次性干粉吸入器
Project 3: Cyclops™, a Low-COG Innovative Preloaded-disposable DPI with Fast to Market Applications

16:05-16:25

CHEN Jiehui
Asia CEO, iDNA
项目 4: 基于肺癌的多病种一体化筛查项目
Project 4: iDNA-Providing Turn-key Solution for Lung Cancer Based Multi-Comorbidities Screening Program

16:25-16:45

Ernst Elhorst
CEO, SuperSeton
项目 5: 操作简单、安全可靠的创新型肛瘘挂线
Project 5: SuperSeton-A smooth, Simple and Safe Innovative Solution for Anal Fistula Drainage

16:45-17:05

Jeroen Kodde
CEO, Kaminari Medical
项目 6: 结合超声与光学成像技术的新型冠状动脉血管重建术
Project 6: Kaminari Medical: Combining Ultrasound and Optical Imaging to Revolutionize Coronary Revascularization

17:05-17:25

Jaap Delange
CEO, Respiosa BV
项目 7: 用于治疗阻塞性睡眠呼吸暂停综合症的微创手术植入物
Project 7: Respiosa OSA Implant Technology

国际云路演专场——加拿大
Virtual International Roadshow - Canada

22 SEP TUE

主持人：米璐璐，加拿大驻沪总领事馆商务处 生命科学商务专员
Moderator: MI Lulu, Life Sciences Trade Commissioner, Consulate General of Canada in Shanghai

09:30-09:35
Dave Murphy
加拿大驻沪总领事
Consul General, Consulate General of Canada in Shanghai
开场致辞 Welcome Remarks

09:35-09:50
Karimah Es Sabar
CEO & Partner, Quark Venture LP
开场报告：在全球大流行中，加拿大生命科学生态系统和耐力的主要优势
Keynote Speech: Key Strengths for Canada's Life Science Ecosystem and Endurance Amidst a Global Pandemic

09:50-10:10
Bill Hunter
President & CEO, Canary Medical Inc.
项目 1: Canary——智能慢病管理和虚拟医疗的交叉创新

10:10-10:30
Mohammad Qadir
President & CSO, Fusion Genomics Corp.
项目 2: 用于预防传染病的多重基因诊断技术
Project 2: Massively Multiplex Diagnostics for Infections Diseases

10:30-10:50
Karim Lalji
CEO, Microbion Pharma Corp.
项目 3: Pravibismane: 治疗生物膜感染的创新疗法
Project 3: Pravibismane: Breakthrough Therapy against Biofilm-related Chronic Infections

10:50-11:10
ZHANG Hao
CEO, Onestep Laboratories Inc.
项目 4: 独创“芯片级”免疫分析及血液分析原材料
Project 4: Raw Materials for IVD

11:10-11:30
ZHANG Zaihui
CSO & VP R&D, Signalchem Lifesciences Corp.
项目 5: SLC-391——用于癌症治疗的临床阶段小分子 AXL 抑制剂
Project 5: SLC-391 - A Clinical Stage Small Molecule AXL Inhibitor for Cancer Therapy

11:30-11:50
Michael Parr
President & CSO, Sitka Biopharma Inc.
项目 6: 突破障碍：运用纳米技术治疗膀胱癌
Project 6: Breaking through Barriers: Nanotechnology Therapeutics Platform with a Lead Program for Bladder Cancer

主办方介绍

Introduction of 2020 CBIIC Hosts

中国医药创新促进会

中国医药创新促进会（原名“中国医药工业科研开发促进会”，简称“中国药促会”），英文名称：China Pharmaceutical Innovation and Research Development Association（PhIRDA），成立于 1988 年，是经国家民政部登记注册的非营利性全国性 4A 级社会组织。

中国药促会秉承“创新、产业化、国际化”的宗旨，以临床需求为导向，长期致力于“产学研用资”紧密结合，促进医药行业创新发展，已经成为集医药创新研发型企业、科研机构、临床研究机构、创新服务机构和医药投资机构所组成的医药创新产业化促进平台，目前有会员单位 144 家。中国药促会已成立了药物研发专业委员会、药物临床研究专业委员会、医药政策专业委员会、医药创新投资专业委员会、创新研发服务专业委员会和心血管药物临床研究专业委员会，形成了以创新为核心，以促进创新为目标的涵盖药物研发、生产、使用以及投融资的全链条组织构架，并作为国际药品制造商协会联合会（IFPMA）的成员继续拓展国际交流渠道。

中国药促会工作内容主要包括：一是，开展医药政策研究，为我国医改事业、完善药物政策和医药产业发展建言献策；二是，通过举办各种论坛、发布会、大型会议等活动，促进会员单位乃至整个医药产业的相互交流、创新发展；三是，通过与国内外医药行业协会、企业、科研机构和外国驻华使馆合作，推动国际医药产业的多方位、多维度合作交流，为会员单位搭建国际交流平台；四是，践行国家创新驱动发展战略指导精神，为会员单位拓宽医药创新投融资渠道、搭建合作平台，推动社会资本加大对初创及研发型企业自主创新项目的投入，营造更有吸引力的医药创新投资环境；五是，为会员单位提供医药信息搜集、整理、评价服务，包括编辑每日《医药信息简报》、每周《国际医药产业发展动态与研发信息简报》等内部电子刊物以及中国药促会官方网站、微信公众号等服务平台。

中国药促会将围绕办会宗旨，不断拓展服务内涵和外延，做好政府与会员企业的桥梁和纽带，维护会员合法权益，加强行业自律，推动我国医药产业的创新和可持续发展，为加快我国经济社会发展、保障人民群众健康不断做出贡献！



PhIRDA

Founded in 1988, China Pharmaceutical Innovation and Research Development Association (PhIRDA), formerly named China Pharmaceutical Industry Research and Development Association, is registered as a non-profit 4A social organization by the Ministry of Civil Affairs of China at national level.

PhIRDA has been exerting great effort on "academia-industry-investment collaboration", which centers on the principle of "innovation, industrialization, internationalization", and persists in innovation to achieve unmet clinical requirements. As a platform facilitating the industrialization of pharmaceutical innovation, PhIRDA currently has 144 members mainly consists of pharmaceutical R&D enterprises, research institutions, clinical institutions, R&D Services companies and investment institutions focusing on pharmaceutical innovation. Moreover, PhIRDA has established the following Specialty Committees: Drug R&D, Clinical Research, Medicinal Policy, Pharmaceutical Innovation Investment and Innovation R&D Services and Clinical Research on Cardiovascular Drugs, forming a fully functional organization structure focusing on innovation, aiming to promote the development of innovation, covering the whole industrial chain, including drug R&D, manufacturing, using, investment and capital market. PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.

Major work of PhIRDA includes: first, to conduct policy researches, propose valuable suggestions on healthcare reform and the development of pharmaceutical industry; second, to promote communication and innovative development of our members and even the whole pharmaceutical industry through forums, press-conferences, summits, etc.; third, to make efforts to establish an international exchange platform for our members through cooperation with foreign embassies and foreign associations to stimulate comprehensive communication between China and foreign countries in pharmaceutical field; fourth, to practice the guiding spirits of national innovation-driven development strategy, to broaden the investment and financing channels of pharmaceutical innovation, to build the cooperation platform for our members, and to promote social capitals to pay more attention on investment in innovative projects of start-up and R&D enterprises to create a more attractive environment of pharmaceutical innovation and investment; fifth, to improve the website and WeChat official account of PhIRDA and provide collecting, arranging, revising service of pharmaceutical information, which includes the following internal e-magazines such as the *daily Pharmaceutical Information Brief*, *the weekly International Pharmaceutical Development Tendency and Research Information Brief*.

PhIRDA will center on our principle, continuously expand services, build a bridge between the government and our members, maintain legitimate rights and interests of members, strengthen self-discipline, promote healthy development of Chinese pharmaceutical industry, making constant contributions to the greater economic development of the country and public health.

中国医疗器械行业协会

中国医疗器械行业协会（CAMDI）成立于 1991 年，是由从事医疗器械研发、生产、经营、投资、产品检测、认证咨询及教育培训等医疗器械产业相关工作的单位或个人在自愿的基础上联合组成的全国范围的行业性非盈利社会组织，具有社会团体法人资格。

协会的宗旨是代表并维护会员单位的共同利益及合法权益，促进中国医疗器械行业健康发展。 协会遵守国家宪法、法律、法规和国家政策，遵守社会道德风尚；业务主管单位为国务院国有资产监督管理委员会，并接受国家食品药品监督管理总局的业务指导。

中国医疗器械行业协会目前有分会及专业委员会 40 余个，拥有各类会员近 4000 家。

香港交易所

香港交易及结算所有限公司（香港交易所）是世界主要的交易所集团之一，业务范围包括股票、大宗商品、衍生产品、定息及货币产品。香港交易所是全球领先的新股融资中心，也是香港唯一的证券及衍生产品交易所和结算所营运机构，为国际投资者提供进入亚洲最活跃市场的渠道。

香港交易所透过全资子公司伦敦金属交易所（LME）和 LME Clear Limited，运营全球领先的工业金属交易市场。2018 年，香港交易所在中国深圳设立的前海联合交易中心开业，迈出大宗商品业务发展的又一步。

香港交易所是与中国内地市场互联互通的先行者。2014 年，香港交易所推出沪港通机制，让国际投资者可以通过香港直接投资中国内地股市；沪港通开启的互联互通机制先后于 2016 年及 2017 年拓展至深港通及债券通。

www.hkexgroup.com

艾美达（北京）医药信息咨询有限公司

艾美达（北京）医药信息咨询有限公司（简称“艾美达”）成立于 2014 年，是一家专业的医药行业咨询服务提供商，同时也是医药产业链资源整合服务商。公司依托强大的医药行业国内外资源，以国家产业政策对市场的影响为导向，医药卫生行业大数据为基础，通过专业的数据分析，结合药物经济学和市场准入流程，利用学术活动平台为医药企业提供整套技术及市场解决方案，并为投资机构提供技术和政策咨询服务。

CAMDI

Founded in 1991, China Association for Medical Devices Industry (CAMDI) is a non-profit social organization with corporative qualification. As a national medical devices industry association, CAMDI is established on a voluntary basis by organizations and individuals engaged in the research and development, production, operation, investment, product testing, certification and consultation, and training in relation to medical devices.

The purpose of CAMDI is to represent and safeguard the common interests and legitimate rights of its members, and to promote the healthy development of China's medical devices industry. CAMDI abides by the State's constitution, laws, regulations and policies, observes social ethnics, and receives guidance and supervision of the State-owned Assets Supervision and Administration Commission, receives guidance of China Food and Drug Administration.

Currently, CAMDI runs over 40 branches and specialized committees and has more than 4,000 members.

HKEX

Hong Kong Exchanges and Clearing Limited (HKEX) is one of the world's major exchange groups, and operates a range of equity, commodity, fixed income and currency markets. HKEX is the world's leading IPO market and as Hong Kong's only securities and derivatives exchange and sole operator of its clearing houses, it is uniquely placed to offer regional and international investors access to Asia's most vibrant markets.

HKEX is also the global leader in metals trading, through its wholly owned subsidiaries, The London Metal Exchange (LME) and LME Clear Limited. This commodity franchise was further enhanced with the launch of Qianhai Mercantile Exchange, in China, in 2018.

HKEX launched the pioneering Shanghai-Hong Kong Stock Connect programme in 2014, further expanded with the launch of Shenzhen Connect in 2016, and the launch of Bond Connect in 2017.

www.hkexgroup.com

iMeta

iMeta Health Information Consulting Co., Ltd. established in 2014, is a professional consulting provider and a service provider offering integrated resource in pharmaceutical industry chain. Relying on domestic and global rich resource in pharmaceutical industry, taking national industrial policies as guide and on the basis of big data from medical and health industry for professional data analysis, iMeta combinates market access with pharmacoeconomic and fully utilizes academic platform to provide technical service and market solutions for pharmaceutical enterprises, and offer technical suggestions and policy advice for investment institutions.

博　沛
荷兰王国驻华大使馆卫生、福利和体育参赞

Peter A. Bootsma
Counselor for Health, Welfare and Sports, Embassy of the Kingdom of the Netherlands

博沛先生，医学博士，2014 年任荷兰驻华大使馆卫生、福利和体育参赞。1999 至 2003 年、2010 至 2014 年，任荷兰驻华盛顿大使馆卫生参赞，负责美国和加拿大区域。自 2006 年，任荷兰卫生监察局地区主任。2003 至 2006 年，任荷兰卫生部创新、职业和道德处处长。赴华盛顿之前，他是荷兰国家公共卫生研究院国际合作局副局长，负责对西欧、东欧和前苏联国家的技术援助项目和卫生发展项目。1985 至 1991 年，他负责对中东、亚洲和非洲发展中国家的卫生保健和技术援助项目。他曾在中东及其他国际机构做过 5 年的全科医生。

Peter A. Bootsma, M.D. is the Counselor for Health, Welfare and Sports at the Embassy of the Kingdom of the Netherlands in Beijing since 2014, liaising with the Chinese Government and Chinese private sector in health, welfare and sports. Previously, Mr. Bootsma was Counselor at the Royal Netherlands Embassy in Washington D.C. from 1999-2003 and 2010-2014, representing Dutch health, welfare and sports interests in the United States and Canada. Mr. Bootsma was Regional Director at the Netherlands Health Care Inspectorate as from 2006 and (Deputy) Director for Innovation, Professions and Ethics at the Netherlands Ministry of Health from 2003-2006. Prior to this Washington D.C. assignment, he was Deputy Head of the Bureau for International Cooperation at the Netherlands' National Institute of Public Health. In that position, he was responsible for technical assistance projects and health development projects in Western and East-European countries and countries of the former Soviet Union. From 1985-1991, he was responsible for health care and technical assistance projects in a variety of developing countries in the Middle East, Asia and Africa. Mr. Bootsma started his career as a General Practitioner in the Middle East and other international settings.

梁　燕
荷兰王国驻华大使馆卫生、福利和体育处生命科学和医学官员

Sunny LIANG
LSH Officer, Department of Health, Welfare and Sport, Embassy of the Kingdom of the Netherlands

梁燕，生命科学和医学官员，自 2007 年底任职于荷兰王国驻华大使馆卫生、福利和体育部门。她主要负责荷兰驻华使馆生命科学和医学、养老和体育行业的相关工作。她工作的重要内容之一是积极促进相关行业中荷产业界的商业对接，包括协助荷兰中小企业在华寻找研发、市场，投融资等合作伙伴。

梁燕毕业于大连医科大学第二附属医院肾内科专业，曾先后就职于首都儿科研究所附属儿童医院，国际 SOS 救援中心，马士基（中国）航运有限公司，以及无国界医生组织 MSF 等。

Sunny Liang, Life Science and Health Officer. She is part of the Department of Health, Welfare and Sports (VWS) of the Embassy of the Kingdom of the Netherlands since the end of 2007. Sunny is the focal point at the Embassy for the Life Science & Health (LSH), elderly care, and sport sectors. One important part of her work focuses on actively assisting relevant Dutch SME's in reaching out to potential Chinese partners, including R&D, marking partners, and investors, etc. Sunny has a master degree of Nephrology from the Dalian Medical University. She used to work at the Beijing Children's Hospital of Capital Institute of Pediatrics, International SOS, Maersk China, and MSF, etc.

穆大纬
加拿大驻上海总领事

Dave Murphy
Consul General, Consulate General of Canada in Shanghai

穆大纬先生于 2019 年 10 月被任命为加拿大驻上海总领事。在来上海之前，穆大纬先生担任加拿大驻华大使馆商务公使，这是他在北京的第二个任命。穆大纬先生的海外任职经历包括：在布宜诺斯艾利斯担任经济和贸易参赞和在台北加拿大贸易办事处担任贸易与投资主任。穆大纬先生于 1991 年加入加拿大外交及国际贸易部，曾先后担任媒体关系官员，中国和蒙古司的副主任，和投资合作项目主任。此外，穆大纬先生曾担任加拿大国际开发署产业合作项目总干事并在蒙特利尔国际的国际组织部担任副总裁。
穆大纬先生在麦吉尔大学获得农业工程科学学士学位。他拥有在蒙特利尔的卡夫食品公司担任项目工程师的私营部门工作经验。穆大纬先生会说普通话和西班牙语。

Dave Murphy was named Consul General of Canada in Shanghai in October, 2019. Most recently, Mr. Murphy was Minister (Commercial) at the Canadian Embassy in Beijing, his second assignment to that mission. He has also served overseas as Counsellor (Commercial-Economic) in Buenos Aires, and as Director (Trade and Investment) at the Canadian Trade Office in Taipei. Mr. Murphy joined the Canadian Public Service in 1991, and served in the Department of Foreign Affairs and International Trade as Media Relations Officer, Deputy Director in the China and Mongolia Division, and Director of the Investment Cooperation Program. He was seconded to the Canadian International Development Agency as Director General, Industrial Cooperation Program, and to Montreal International as Vice President (International Organizations).
Mr. Murphy holds a Bachelor of Science in Agricultural Engineering from McGill University, and gained private sector experience as Project Engineer with Kraft General Foods in Montreal. He speaks Mandarin Chinese and Spanish.

Karimah Es Sabar
Quark Venture 首席执行官兼合伙人
加拿大政府经济战略委员会（健康与生物科学）主席
加拿大政府工业策略委员会成员

Karimah Es Sabar
Chief Executive Officer & Partner, Quark Venture LP
Chair, Health & Biosciences, Economic Strategy Table (Government of Canada)
Member, Industry Strategy Council (Government of Canada)

Karimah Es Sabar 女士是加拿大生命科学领域公认的领袖，拥有丰富的全球经验，她是药物研究与发展中心（CDRD）的首席执行官兼总裁；曾担任过 BC 省生命科学行业协会首席执行官兼总裁。她不仅在大型制药公司担任高级管理职位时有杰出的表现；她还成功培养、孵化了多家初创公司。
Es Sabar 女士因卓越领导力和开创性贡献数次荣获表彰，包括加拿大 Top100 最具影响力女性。Es Sabar 女士在众多健康科技公司董事会以及研发 / 非营利组织任职。

A highly-recognized Canadian life sciences leader with global experience, she was CEO & President of the Centre for Drug Research and Development (CDRD); CEO & President of LifeSciences BC; she has had a distinguished record of senior management positions in big pharma; and she helped found and lead several startup companies internationally.
Ms. Es Sabar has received multiple awards and recognitions for her leadership and pioneering work, including Canada's Most Powerful Women: Top 100 Award. Ms. Es Sabar serves on numerous boards of health technology companies as well as R&D and not-for-profit organizations.

米璐璐
加拿大驻沪总领事馆商务处 生命科学商务专员

MI Lulu
Life Sciences Trade Commissioner, Consulate General of Canada in Shanghai

米璐璐自 2016 年起任职于加拿大驻沪总领事馆商务处。作为加拿大商务专员服务（TCS）的一员致力于推动和促进加中双边在学术、产业、贸易及投资等层面和领域的双向互动合作，以及两国之间企业和商业机构之间的专业对接；特别是协助加拿大中小型创新企业和机构在华寻找合作伙伴，拓展研发、商业转化和投融资机会。她取得乔治华盛顿大学商科硕士学位，此前曾就职于毕马威管理咨询。

MI Lulu has been a member of the Canadian Trade Commissioner Service (TCS) global network since 2016. With presence in more than 14 cities across China and over 120 years of professional experiences, TCS facilitates Canadian companies' in-market professional development and strategic bilateral engagements with on-the-ground business stakeholders. She graduated from The George Washington University with a master's degree in business, and worked in KPMG's Management Consulting practice.

路演项目介绍
Introduction of Roadshow Projects

国际云路演专场——荷兰
Virtual International Roadshow - Netherlands

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Troels Jordansen	CEO, Glycostem	癌症杀手：自然杀伤细胞抗癌药 NK Cells: The Killer of Cancer

项目简介

Glycostem 成立于 2007 年，一直专注于自然杀伤细胞（NK）疗法的研究，目前有约 40 名员工。基于脐带血干细胞 CD34+，Glycostem 开发了可以现货供应的自然杀伤细胞产品 oNKord®。I 期临床试验的结果表明 oNKord® 安全无副作用；追踪存活率，第一年达到 80%；五年达到 50%。针对急性粒细胞白血病（AML）和多发性骨髓瘤（MM）的临床试验预计于十月、十一月间启动。

Glycostem 拥有 GMP 车间洁净室，其独特的封闭式制造系统确保最终产品达到最高标准。生产过程中不需要癌细胞作为饲养细胞，因此最终产品没有包含癌症 DNA 片段或癌细胞的风险。

Glycostem 是自然杀伤细胞和 CAR-NK 细胞领域公认的领导者，oNKord® 已经授权给日本和韩国经销商，同时 Glycostem 也在积极开发和准备 CAR-NK 和 TCR-NK 前期临床活动，已经在这一领域达成了两项全球交易。

Project Introduction

Glycostem has developed NK-cells therapies and a solid GMP manufacturing process. Our NK-cell therapies include naked NK-cells (oNKord - un-manipulated) and several CAR-NK products. We are about to (October) take oNKord into pivotal trials for AMlL and MM patients. oNKord is already out-licensed in Japan and Korea but we are looking for potential partners for China and other Asian territories and are interested in exploring territory specific cancers such as liver and lung cancer. For CAR-NK we already have two global partners for whom we are developing CAR-NK products and expect to be in phase I clinical trials by 2021/2022. We are actively looking for partners for co-development of future CAR-NK products.

Since June 2019 we have had GMP license for our in-house cleanroom. In this cleanroom we have a completely closed manufacturing system which we believe is the first of its kind. This means that we will not have any contamination and can operate in a class-C environment which is less capital intensive that class A/B.

Glycostem is currently raising $40/$50 million in a cross over found raise and by 1st half 2021 we expect to be listed on NASDAQ.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Axel Mescheder	CEO, Cristal Therapeutics	改善癌症和其他疾病治疗效果的纳米药物 Customized Nanomedicines with Superior Therapeutic Profiles

项目简介

CriPec® 纳米药物平台通过改善药物动力学与生物学分布，提高药物的耐受性与组织靶向性。CriPec® 可与小分子、多肽、寡核苷酸药物结合，既可调控药物释放速率，也可经靶向配体功能化提升选择性。CriPec® 纳米药物生产步骤简易、成本低，大规模（GMP）生产成熟且可制备冻干剂型。

先导产品 CPC634（CriPec® 包埋的抗肿瘤药多西他赛）已进入实体瘤 II 期临床试验。临床数据证实相较传统多西他赛，CPC634 延长了药物体循环时间、提高了安全性并显著提升药物的肿瘤摄取。

公司的点击化学专利技术 CliCr® 可高效合成各类新型偶联物，CriVac® 平台则可通过模拟病毒特性，快速提供应对不同病原体的疫苗方案。

Project Introduction

Cristal Therapeutics is a clinical stage company developing innovative products for improved treatments of cancer and other diseases. The CriPec® nanomedicine platform improves tolerability and enabling selective tissue targeting of therapeutic agents via prolonged pharmacokinetics and improved biodistribution. CriPec® can be combined with small molecules, peptides and oligonucleotides, with tuneable drug release kinetics and option to increase selectivity by functionalizing CriPec® surface with targeting ligands. The manufacturing of CriPec® nanomedicines is a straightforward with low cost of goods, and large (GMP) scale production is already in place including freeze-drying.

The lead product CPC634 (CriPec® entrapped docetaxel) is in clinical phase 2 for the treatment of solid tumors. The clinical data so far have demonstrated prolonged systemic circulation, improved safety and significantly enhanced tumour uptake as compared to the conventional docetaxel.

The click chemistry platform "CliCr®" generates superior and novel conjugate products, whilst CriVac® platform can generate virus mimics and thereby offers a prophylactic vaccination strategy readily adaptable to different pathogenic threats.

Jeroen Tonnaer	BD&Licensing, PureIMS	可快速投放市场的低成本预装式一次性干粉吸入器 Cyclops™, a Low-COG Innovative Preloaded-disposable DPI with Fast to Market Applications

项目简介

PureIMS 是一家进行临床阶段研究的公司，基于其专有的、预装和一次性 DPI（干粉吸入器）平台 Cyclops™，开发了一系列快速创造价值的许可机会。Cyclops™ 是经 CE 认证的医疗器械。它的设计和功能性具有低成本的特点，并受专利保护，直到 2034 年。现已上市一种 Cyclops™ 产品（用于囊性纤维化）并在同情用药方案下予以报销。

PureIMS 成立于 2014 年，是格罗宁根大学和医疗设备制造商 IMDS 的子公司，总部位于荷兰 Roden。该公司是在种子资金的基础上成立的，目标是进行约 2500 万欧元的 A 轮融资。通过融资的收益，公司将实施其两个牵头项目（神经学和过敏症研究的第二阶段），并通过 505(b)(2)/10(3) 条规定获得市场许可。此后公司将开发三个符合第 505(b)(2)/10(3) 条规定的后续项目，直至达到人类试点 –PK 里程碑，并将获得许可。Cyclops™ 平台可进行半独家许可。

Project Introduction

PureIMS is a clinical stage company developing a portfolio of rapidly value creating licensing opportunities based on its proprietary, preloaded and disposable DPI (dry powder inhaler) platform Cyclops™. Cyclops™ is a CE-marked medical device. Its design and functionality imply low COG and are patent protected until 2034. One Cyclops™ application (colistin for the indication cystic fibrosis) is on the market and reimbursed under a compassionate use regimen.

PureIMS was established in 2014 as a spin-off from the University of Groningen and medical device manufacturer IMDS and is based in Roden, The Netherlands. The company was founded on the basis of seed funding. The company is aiming at a Series A financing round of ~EUR 25M. Through the proceeds of the financing round the company will pursue its two lead programs (Phase 2 in neurology and allergy) to market authorization via the 505(b)(2)/Article 10(3) pathways, and develop three follow-on 505(b)(2)/Article 10(3)-qualifying programs in different indications until the human pilot-PK milestone upon which they will be out-licensed. The company's platform Cyclops™ is available for semi-exclusive licensing.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
CHEN Jiehui	Asia CEO, iDNA	基于肺癌的多病种一体化筛查项目 iDNA-Providing Turn-key Solution for Lung Cancer Based Multi-Comorbidities Screening Program

项目简介

iDNA 是唯一一家负责欧洲最大的肺癌筛查实验项目——4ITLR 的私人研究所。iDNA 依托国际领先的 NELSON 肺癌筛查方案，以及对肺癌、慢阻肺、冠脉病、肺炎患者胸部 CT 影像的深度理解，可以为医院 / 体检中心提供低假阳性、高精准度的肺癌筛查全流程解决方案。在筛查肺癌的同时，允许单次扫描辅助筛查慢阻肺、冠脉病、肺炎（包括新冠肺炎），提升筛查项目的成本效益。iDNA 的全流程解决方案包括且不限于：高危人群的筛选与招募、信息系统数据管理、CT 设备调试与校准、现场 / 远程 CT 影像数据评估、医护人员的标准化培训、流程管理以及全球领先的 AI 筛查软件。

Project Introduction

iDNA is the only private institution who is responsible for the CT imaging in a biggest European Lung Cancer screening project within Horizon 2020 program. iDNA has the experience in carrying out lung cancer screening programs in large population. In reliance on iDNA's advanced lung cancer screening method based on NELSON study, as well as its deep understanding in CT images of lung cancer, COPD, coronary artery disease and pneumonia (also Covid-19), iDNA can provide hospitals, health check centers with low false-positive and highly accurate turn-key lung cancer screening solution allowing diagnosis of lung cancer, COPD, coronary artery disease and pneumonia with only one scan. iDNA's turnkey solution includes but not limited to implementing high-risk population profiling, recruitment, (ICT) data management, CT calibrating technology, on-site/remote evaluating CT imaging data, training on-site personnel on SOPs, and state-of-the-art AI software.

Ernst Elhorst	CEO, SuperSeton	操作简单、安全可靠的创新型肛瘘挂线 SuperSeton-A smooth, Simple and Safe Innovative Solution for Anal Fistula Drainage

项目简介

SuperSeton 是一种用于肛瘘管引流的光滑、简单且安全的解决方案，可显著减轻患者在手术中的疼痛感和术后的不适感。相比于现有肛瘘管引流手术中常用的带有绳结的挂线，SuperSeton 没有绳结且表面光滑，同时配备了拥有专利设计的创新连接头和一次性连接器，使用起来安全、灵活，可以在几秒钟内手动完成闭环动作。该产品已在欧洲获得 CE 认证 IIA 类证书，并已在欧洲市场销售。SuperSeton 目前已经在欧洲、美国、印度、日本和中国申请专利保护。与此同时，我们准备从中国寻求合作伙伴（和投资者），使我们也能够为中国患者提供服务。

Project Introduction

SuperSeton is a smooth, simple and secure solution for fistula drainage that prevents unnecessary irritation and discomfort for patients. Knotless and smooth, SuperSeton features an innovative closure that is secure and flexible, and can be applied manually in seconds with the patented disposable applicator. The product is registered in Europe as a CE Class IIA device and is available on the European market. Currently patients are treated and enjoying the comfort provided by SuperSeton

As we have filed for patent protection in Europe, US, India, Japan and China, we are ready to seek partnerships (and investors) from China, enabling us to also serve the Chinese patients. In the end, the SuperSeton has been developed and designed with the patient in mind, providing comfort where needed.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Jeroen Kodde	CEO, Kaminari Medical	结合超声与光学成像技术的新型冠状动脉血管重建术 Kaminari Medical: Combining Ultrasound and Optical Imaging to Revolutionize Coronary Revascularization

项目简介

Kaminari 通过将超声和光学成像结合到血管内光声（IVPA）设备中，开发出了一种血管内窥镜来对冠状动脉内部进行成像。Kaminari 的 IVPA 系统包括一个用于信号生成和分析的控制台，以及一个带有远端尖端的导管，该导管置于冠状动脉之中。

导管的总长度约为 1.80 m，由一个外套（直径 1 mm）和一个内芯组成，远端带有光声换能器（直径 0.6 mm）。在冠状动脉的数据采集过程中，末端带有换能器的内核被拉回大约 10 厘米，并以每分钟 1200−3000 转的速度旋转。在概念验证的演示中，我们使用了原型导管，该导管达到预期的效果。利用这种技术，可以确定斑块的结构和组成。IVPA 是唯一可以实现此目的的技术。

Project Introduction

Kaminari develops an intravascular catheter to image the coronary arteries by combining ultrasound and optical imaging into an Intra Vascular Photo Acoustic (IVPA) device that will significantly reduce major adverse cardiac events and recatherizations.

Kaminari Medical's IVPA system consists of a console for signal generation and analysis, and a catheter with a distal tip that is placed in one of the coronary arteries.

The catheter has an overall length of ca. 1.80 m and consists of an outer sheath (diameter 1 mm) and an inner core with the photo-acoustic transducer (diameter 0.6 mm) at the distal end. During data acquisition in the coronary artery, the inner core with the transducer at the end is pulled back ca 10 cm and rotated at 1200 - 3000 revolutions per minute. In the proof of concept demonstration we used a prototype catheter that performed sufficiently for the purpose. With this technology the structure and the composition of the plaques can be determined. IVPA is the only technology that can achieve this.

Jaap Delange	CEO, Respiosa	用于治疗阻塞性睡眠呼吸暂停综合症的微创手术植入物 Respiosa OSA Implant Technology

项目简介

Respiosa OSA 植入术（CE 认证 II B 类医疗器械）是一种简单、微创的外科手术植入解决方案，可为由于舌头造成的阻塞性睡眠呼吸暂停症提供最佳治疗。当患者仰卧睡觉时，Respiosa 可防止舌头塌陷入气道。手术可在 30 分钟内完成，有效减少患者创伤，且术后恢复快。术后，植入物可以通过配套的全套仪器进行完全去除。由于 Respiosa 使用了纯天然的材料，患者不会感觉到植入物的存在，材料也不会与身体产出排异反应，因此在附着力方面不存在问题。此外，Respiosa 还可以用于治疗由于舌头阻塞导致的打鼾症状。Respiosa 的设计经过了严格的产品测试、临床专家认可以及广泛的临床前动物研究以及早期的 2 期临床试验。

Project Introduction

Respiosa OSA Implant Technology (Class IIb); a simple, minimally invasive surgically implanted solution to provide optimal therapy for tongue based OSA. Respiosa prevents the tongue from collapsing into the airway when patients sleep on their backs. Designed and tested by world-class developers with ENT surgeons, the novel Respiosa implant system promises to deliver effective, durable and adjustable therapy. The implant can be placed with a 30-minute procedure, offering low trauma and quick recovery. Respiosa's effect is optimized with an in-office adjustment procedure post-surgery. The implant can be completely removed. A removal kit includes all instruments required for a removal procedure. Since Respiosa is natural and unobtrusive, patients don't feel the implant, or interact with it, thus adherence is not an issue. Respiosa's indications will also include tongue-based snoring. Respiosa's design has been refined with robust bench testing, KOL feedback, and extensive preclinical (animal and cadaver) studies as well as an early stage Phase 2 clinical trial.

国际云路演专场——加拿大
Virtual International Roadshow - Canada

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Bill Hunter	President & CEO, Canary Medical Inc.	Canary——智能慢病管理和虚拟医疗的交叉创新

项目简介

Canary Medical 的首个产品是装备有 Canary 健康植入报告处理器（CHIRP）的智能胫骨延长器，与全膝关节置换（TKA）系统配合使用。CHIRP 收集患者一天的步态指标，通过家庭基站将其上传到 Canary 符合 HIPAA 标准的云中，分析后提供给临床医生和患者。它能为外科医生提供大量数据参考，以较低的成本增强医疗团队管理、患者沟通和长期疾病管理。Canary 向 FDA 提交了 CHIRP 及其相关生态系统的 De Novo 510K 申请，被 FDA 授予首个全关节产品“突破性设备”。预计 2020 年下半年提交并在 2021 年上半年获批。

Project Introduction

Canary Medical's first product, the Canary Health Implanted Reporting Processor (CHIRP) smart tibial extension, is designed to be used in conjunction with its world-leading othopaedic partner's Total Knee Arthroplasty (TKA) system. The CHIRP collects patient gait metrics, range of motion, recovery and complication data and uploads this to Canary's HIPAA compliant cloud via a home base station for analysis and presentation to the Clinician and Patient. This rich data set provides Surgeons with the ability deliver healthcare passively and remotely for up to 20 years after surgery resulting in better disease management and lower costs. Canary has received Breakthrough Status from the FDA for the TKA product, a first in total joint products. It is targeting to submission for H2 2020 and anticipates an approval in H1 2021.

Mohammad Qadir	President & CSO, Fusion Genomics Corp.	用于预防传染病的多重基因诊断技术 Massively Multiplex Diagnostics for Infections Diseases

项目简介

Fusion Genomics Corp 的 ONETest™ 泛病原体测试可以响应包括未确诊（特发性）感染在内的众多诊断应用场景，其测试平台的核心技术均已突破概念验证和临床研究阶段。每年因该感染需要入院治疗的美国患者达数百万计，而目前的分子方法无法有效诊断这些感染，导致治疗效率低下、住院治疗负担居高不下以及与抗生素耐药性叠加。由此导致的医疗成本总计超过 270 亿美金。

Fusion Genomics 已经与包括加拿大 Sunnybrook Health Sciences Centre、佛罗里达大学、西雅图儿童医院等多家杰出研究机构合作验证并探索 ONETest™ 的商业转化问题。公司的愿景是提供基于基因组信息的准确诊断，以经济有效、及时并低成本的方式，指导治疗、检测抗生素耐药性和识别宿主（人类）疾病易感性标记，从而造福有需要的患者群体。

Project Introduction

Fusion Genomics's product, ONETest, has broad application and would reduce hospital costs and save lives by diagnosing diseases that are currently impossible or difficult to detect. Today, this category of diseases represents a surprising percentage of hospital admissions and costs the US healthcare system $27 billion each year. All technologies necessary for such a test have been developed to the proof-of-concept or clinical study stage and are now being commercialized by Fusion Genomics.

Fusion Genomics has partnered with world class institutions, such as Sunnybrook Health Sciences Centre, University of Florida, Dutch National Institute and Seattle Children's Hospital, to validate the ONETest and plans to commercialize it soon. Fusion Genomics' mission is to make these genomic tests for infectious diseases as ubiquitous and cost-effective, as today's PCR and antibody tests. The ultimate aim is to have an automated, easy to use, rapid test that costs just $100 and can spot novel viruses as they emerge in humans.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Karim Lalji	CEO, Microbion Pharma Corp.	Pravibismane： 治疗生物膜感染的创新疗法 Pravibismane: Breakthrough Therapy against Biofilm-related Chronic Infections

项目简介

Microbion 是一家临床阶段的制药公司，重点开发突破性的疗法，用于治疗耐药性和危及生命的感染。Microbion 的主要药物为 Pravibismane（普拉维比斯曼）一首个已知的广谱抗感染药物，能够对抗各种耐药细菌 / 超级细菌、高度耐药真菌物种，可高效破坏细菌生物膜，并防止其形成。

Microbion 的药物开发项目针对医疗需求高度未满足的专业市场，预计销售额峰值超过 40 亿美元。Microbion 的局部 / 部分 Pravibismane 试验处于临床 II 期，用于治疗糖尿病足部溃疡（DFI）和整形外科植入物感染。在超过 325 个受试者中，该局部试验已被证明耐受性良好，具有疗效。

Microbion 正在募集资金，用于 DFI 中的 II 期概念验证，以及推进囊性纤维化（CF）患者的第 1b 期吸入临床试验。

Project Introduction

Microbion is a clinical-stage pharmaceutical company developing breakthrough therapies for treatment of drug-resistant and life-threatening infections. Our lead drug candidate, pravibismane, is a new class of broad-spectrum anti-infective with combined potency against a wide range of resistant bacteria, highly resistant fungal species, and an unprecedented ability to prevent and eradicate bacterial biofilms.

Microbion's topical/local pravibismane program is in Phase 2 for the treatment of diabetic foot ulcer (DFI) and orthopedic infections while the inhaled program for cystic fibrosis (CF) related- and non-tuberculous mycobacterial- lung infection, has been awarded over $17M in funding from CARB-X and the Cystic Fibrosis Foundation and Orphan Drug designation (for CF-related infection) from the FDA, is expected to start phase 1 studies in H2 2021. Microbion's drug development program targets specialty markets with high unmet medical need and represent over $4B in peak sales opportunity.

Microbion is seeking funding to complete Phase 2 proof of concept in DFI and advance inhaled program through Phase 1b.

ZHANG Hao	CEO, Onestep Laboratories Inc.	独创“芯片级”免疫分析及血液分析原材料 Raw Materials for IVD

项目简介

Onestep Lab 公司是一家致力于研发世界最前沿的医疗诊断试剂原材料的创新公司，目前已拥有多项“芯片”级发明，应用在各个不同的领域。例如，美国发明专利 US9714939 是应用在酶免疫分析方法学上，可应用在传染病检测，癌症检测，抗体药筛选；美国发明专利 US10597352 是应用在水中的氯监测，可应用在肾病透析病人的透析水监测。公司的目标是成为世界一流的医疗原材料公司，为科学家们提供更好的产品和服务，从而造福人类。

Project Introduction

Onestep Laboratories Inc. draws upon years of experience in biochemistry and diagnostics to develop leading-edge reagents for biological laboratories. Our goal is to provide fellow scientists with high quality, cost effective products. Onestep Laboratories Inc. has developed several products including QuickBlu TMB substrate (US 9714939) for ELISA, TMB solution (US 10597352) for monitoring total chlorine in dialysis water and QuickRedTM Nucleus Stain for live cell imaging.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
ZHANG Zaihui	CSO & VP R&D, Signalchem Lifesciences Corp.	SLC-391——用于癌症治疗的临床阶段小分子 AXL 抑制剂 SLC-391 - A Clinical Stage Small Molecule AXL Inhibitor for Cancer Therapy

项目简介

SLC-391 是具有高活性、高选择性、低毒性和药物性质优异的临床阶段的小分子 AXL 抑制剂，具有适合的半衰期和很高的生物利用度 (>50%)。在非小细胞肺癌动物模型实验中，它与厄洛替尼和紫杉醇联用在抑制肿瘤生长方面显示出强大的协同作用。在 AML 白血病模型和 PDX 模型中，与 BCL−2 抑制剂 venetoclax 的联用显示出在减少白血病负担和增强白血病动物存活率方面的强大协同效应。在 CT−26 结肠癌同基因癌症动物模型实验中，该化合物显示具有调节和提高机体固有性免疫功能以及继发性免疫功能的能力。该化合物在与 PD−1 单克隆抗体的组合治疗中表现出很强的协同效应。目前，SLC−391 正在加拿大的多个癌症中心进行 I 期安全性临床实验，剂量扩增实验阶段预计将于 2020 年底完成。

Project Introduction

SLC-391 is clinical stage small molecule AXL inhibitor with good potency and selectivity with desirable pharmaceutical properties. The pharmacokinetic studies in rodents and dogs indicated that SLC-391 has high bioavailability with a simple suspension formulation (>50%). Moreover, it has exhibited a strong synergistic effect in tumour growth inhibition in combination with erlotinib and paclitaxel in NSCLC xenograft models and demonstrated a strong synergistic effect in decreasing leukemia burden and enhancing survival of leukemic animals in a novel combination approach with BCL-2 inhibitor venetoclax in aggressive xenotransplant AML leukemic models and PDX models. In a CT-26 colon cancer syngeneic model, SLC-391 played a role in modulating both the innate and adaptive immune responses and demonstrated a synergistic effect in tumour growth inhibition and overall survival in combination with an anti-PD-1 antibody. Currently, SLC-391 is under phase I safety clinical evaluations in multi-cancer centres in Canada and the dose expansion phase is anticipated to be complete by the end of 2020.

Michael Parr	President & CSO, Sitka Biopharma Inc.	突破障碍：运用纳米技术治疗膀胱癌 Breaking through Barriers: Nanotechnology Therapeutics Platform with a Lead Program for Bladder Cancer

项目简介

云杉（Sitka）生物制药公司是一家临床前生物技术公司，专注于开发具有突破性的纳米粒子平台技术，以增加药物在难以穿透的组织中的吸收。我们正在开发的领先药物（STK-01），最初针对肿瘤适应症，以解决膀胱癌膀胱内化疗的吸收挑战，以及卵巢癌腹腔内给药的问题。

我们的纳米粒子平台技术用途广泛，与其他纳米输送系统相比具有独特的优势，特别适合于治疗目前无效或不安全的相对局部疾病。膀胱癌被选为我们的治疗目标，因为该病症具有有限的吸收和疗效、或有重大耐受性问题和副作用等挑战。Sitka 的新产品（STK-01）旨在通过将更高浓度的化疗多西紫杉醇直接输送到膀胱壁中，从而克服这些问题并改善治疗效果。

Project Introduction

Sitka Biopharma is a preclinical biotechnology company focused on developing its breakthrough nanoparticle platform technology to increase absorption of drugs in difficult-to-penetrate tissues. Initially targeting oncology indications, we are developing our lead candidate (STK-01) to address the absorption challenge of intravesical chemotherapy for bladder cancer, and later intraperitoneal delivery for ovarian cancer.

Our nanoparticle platform technology is highly versatile, offers unique benefits over other nano-delivery systems, and is particularly well-suited for treating relatively localized diseases where local administration of the therapeutic is possible but is currently ineffective or unsafe. Bladder cancer was chosen for our lead program because it is characterized by therapies that exhibit limited uptake and efficacy, or are associated with significant tolerability issues and side effects. Sitka's novel product (STK-01) is designed to overcome these issues and improve treatment outcomes by delivering a much higher concentration of the chemotherapeutic docetaxel into the bladder wall.